New approach of genetic characterization of group A rotaviruses by the nanopore sequencing method.


Journal

Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839

Informations de publication

Date de publication:
06 2021
Historique:
received: 01 11 2020
revised: 17 02 2021
accepted: 25 02 2021
pubmed: 5 3 2021
medline: 25 11 2021
entrez: 4 3 2021
Statut: ppublish

Résumé

Nanopore sequencing of virus genomes represented by segmented RNA (e.g. rotaviruses) requires the development of specific approaches. Due to the massive use of rotavirus vaccines, the relevance of monitoring the genetic diversity of circulating strains of group A rotaviruses (RVA) increased. The WHO recommended method of multiplex type-specific PCR does not allow genotyping of all clinically significant strains of RVA and identifying inter-strain differences within the genotype. We have described a new principle of amplification of RVA gene segments using six primers for reverse transcription and one universal primer for PCR for nanopore sequencing. The amplification of RVA genome was tested on clinical samples and three phylogenetically distant laboratory RVA strains, Wa (G1P[8]), DS-1 (G2P[4]) and 568 (G3P[3]). The developed protocol of sample preparation and nanopore sequencing allowed obtaining full-length sequences for gene segments of RVA, including the diagnostically significant segments 9 (VP7), 4 (VP4) and 6 (VP6) with high accuracy and coverage. The accuracy of sequencing of the rotavirus genome exceeded 99.5 %, and the genome coverage varied for different strains from 59.0 to 99.6 % (on average 86 %). The developed approach of nanopore sequencing of RVA genome could be a prospective tool for epidemiological studies and surveillance of rotavirus infection.

Identifiants

pubmed: 33662411
pii: S0166-0934(21)00053-7
doi: 10.1016/j.jviromet.2021.114114
pii:
doi:

Substances chimiques

Rotavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114114

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Evgeny Faizuloev (E)

I. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, Moscow, Russia. Electronic address: faizuloev@yahoo.com.

Ramil Mintaev (R)

I. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, Moscow, Russia; FSBI «Center for Strategic Planning and Management of Medical and Biological Health Risks», Laboratory of Gene Therapy, Moscow, Russia.

Olga Petrusha (O)

I. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, Moscow, Russia.

Anna Marova (A)

I. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, Moscow, Russia.

Daria Smirnova (D)

I. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, Moscow, Russia.

Yulia Ammour (Y)

I. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, Moscow, Russia.

Elena Meskina (E)

M. Vladimirsky Moscow Regional Research Clinical Institute (MONIKI), Department of Children's Infections, Moscow, Russia.

Oleg Sergeev (O)

Sechenov First Moscow State Medical University, Faculty of Preventive Medicine, Moscow, Russia.

Sergey Zhavoronok (S)

Belarusian State Medical University, Department of Infectious Diseases, Minsk, Belarus.

Alexander Karaulov (A)

Sechenov First Moscow State Medical University, Department of Clinical Immunology and Allergy, Moscow, Russia.

Oxana Svitich (O)

I. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, Moscow, Russia; Sechenov First Moscow State Medical University, Faculty of Preventive Medicine, Moscow, Russia.

Vitaly Zverev (V)

I. Mechnikov Research Institute of Vaccines and Sera, Department of Virology, Moscow, Russia; Sechenov First Moscow State Medical University, Faculty of Preventive Medicine, Moscow, Russia.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH